CMF and Gully Labs Announce Final Exclusive Drop of Their Co-Created Sneaker

New Delhi, May 25: India-headquartered consumer technology brand, CMF and India’s homegrown sneaker brand known for its storytelling-driven designs, Gully Labs are bringing back the CMF x Gully Labs Xoloni Orange sneaker for one final drop. The exclusive final drop will take place exclusively at Nothing Store, Bengaluru, on 30 May 2026 at 7:00 PM IST, with only a limited number of pairs available.

CMF and Gully Labs Announce Final Exclusive Drop of Their Co-Created Sneaker

As an additional surprise for the community, every successful purchase at the final drop will also include an authentic Royal Challengers Bengaluru (RCB) jersey, signed by the players, celebrating Nothing’s role as the Title Sponsor of RCB during the 2026 T20 season.

The collaboration first began with #DesignCMFKicks, a nationwide design challenge that invited India’s next generation of creators to reinterpret Gully Labs’ signature GL001 silhouette using the colours, textures, and industrial design language of CMF Phone 2 Pro. The challenge received more than 1,000 entries from across the country, turning what could have been a conventional brand collaboration into an open invitation to co-create.

Following community voting and jury evaluation, the winning concept by Dhreetimaan Sarmah from Dhemaji, Assam, was selected and brought to life over a nearly nine-month development journey alongside the teams at CMF and Gully Labs.

The result is a sneaker that carries more than a visual identity. It represents an idea central to both brands: that great design becomes more meaningful when it is participatory, accessible, and shaped by people who care enough to make something new.

Rather than creating a limited edition behind closed doors, CMF and Gully Labs opened the process to the community and turned a creative brief into a tangible object that could move from screen to sketchbook to street. This exclusive drop gives the community a last opportunity to own one of the most exclusive and distinctive creator-led collaborations to emerge at the intersection of technology, design, and culture.

More From Author

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)

SPJIMR hosts Harvard Business School MBA students for global leadership collaboration

Leave a Reply

Your email address will not be published. Required fields are marked *

Win-Back and Re-Engagement Campaigns

Categories